Paraneoplastic β Cell Dedifferentiation in non-diabetic Patients with Pancreatic Cancer.
β cell dedifferentiation was recently proposed as a mechanism of β cell dysfunction, but whether it can be a trigger of β cell failure preceding hyperglycemia in human is uncertain. Pancreatic cancer can cause new-onset diabetes, yet the underlying mechanism is unknown. To investigate whether β cell dedifferentiation is present in non-diabetic pancreatic ductal adenocarcinoma (PDAC) patients, we examined pancreatic islets from 15 non-diabetic patients with benign tumor (Control) and 15 non-diabetic PDAC patients. We calculated the number of hormone-negative endocrine cells and evaluated important markers of β cell dedifferentiation and function in the paraneoplastic islets. We assessed tumor-related inflammatory changes under pancreatic cancer microenvironment, and their influence on β cell identity. We found nearly 10% of non-hormone expressing endocrine cells in non-diabetic PDAC subjects. PDAC islets were dysfunctional, evidenced by low expression of GLUT2 and UCN3, and concomitant upregulation of ALDH1A3 expression and proinsulin accumulation. Pancreatic cancer caused paraneoplastic inflammation with enhanced tissue fibrosis, monocytes/macrophages infiltration and elevated inflammatory cytokines. Moreover, we detected β cell dedifferentiation and defects in GSIS in islets exposed to PANC-1-conditioned medium. In a larger cohort, we showed high prevalence of new-onset diabetes in PDAC subjects, and FBG was found to be an additional useful parameter for early diagnosis of PDAC. Our data provide a rationale for β cell dedifferentiation in the pathogenesis of pancreatic cancer associated diabetes. We propose that β cell dedifferentiation can be a trigger for β cell failure in human, before hyperglycemia occurs.